The company will demonstrate the SVP Essential basic version at the virtual Achema Pulse on June 15 and 16, 2021
Syntegon Technology has launched the SVP Essential, a more cost-efficient version of its Pharmatec SVP process systems for the production of small-volume liquid pharmaceuticals. This portfolio expansion is the company’s response to current industry requirements: “Pharmaceutical manufacturers are increasingly relying on shorter delivery times for their equipment,” said Stephan Hüttner, Head of Engineering Process Systems at Syntegon's Pharmatec product brand in Dresden. “Thanks to the SVP Essential’s standardized modular design, we can supply our customers with a fully automated, ready-to-use system in just six months.”
“With the Essential version of the SVP, both start-ups and pharmaceutical manufacturers in price-sensitive markets benefit from the highest quality 'made in Germany'. We have pre-developed a series of functional modules that can be assembled in a modular system. This reduces the engineering effort and ultimately delivery time,” said Hüttner. With a maximum of two tanks and volume sizes of 50 to 1000 L, the SVP Essential is suited for the production of simple parenterals such as analgesics or insulin, as well as generic drugs, Syntegon says.
The compact system is supplied as a ‘package unit’ with a technology skid in the cleanroom, enabling customers to install it independently. Syntegon’s operatives merely carry out the commissioning on site. Even with the basic version of the SVP, Syntegon uses automation technology. “Customers receive a fully automated, completely closed system with reproducible cleaning and sterilisation. This way we ensure maximum process safety,” Hüttner said.
The SVP Essential reportedly completes Syntegon's Pharmatec SVP portfolio. “Our larger SVP systems with up to five tanks can be easily expanded to include customer-specific isolator systems. Thanks to their sophisticated containment flap system, they are suitable for processing toxic substances up to OEB5 – and are currently used to produce the urgently needed Covid-19 vaccines,” said Hüttner.